Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Background Open partial pancreatoduodenectomy (OPD) represents the current gold
standard of surgical treatment of a wide range of diseases of the pancreatic head but is …

Background Data on perioperative chemotherapy in resectable pancreatic ductal
adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant …

Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …

Cancer is one of the primary causes of worldwide human deaths. Most cancer patients
receive chemotherapy and radiotherapy, but these treatments are usually only partially …

Objective: To investigate the outcome of conversion surgery in patients with metastatic
pancreatic cancer (mPDAC) and to identify patients who may benefit from this approach …

Simple Summary Pancreatic cancer remains a major therapeutic challenge despite medical
advances. The incidence of pancreatic cancer is increasing, and this disease is associated …

Methods: Analyses were carried out to assess the association between clinical
characteristics and margin involvement as well as the effects of individual margin …

Background Multimodal treatment concepts enhance options for surgery in locally advanced
pancreatic ductal adenocarcinoma (PDAC). This review provides an overview of technical …